Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | GLA | P06280 | 2/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | CASP7 | P55210 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1349197 | 0.84 | L3MBTL1 (0.70) | KDM4EALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL4657999 | 0.83 | KDM4E (0.67) | KDM4EALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL28994014 | 0.82 | GPR119 (0.54) | KDM4EALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL16401445 | 0.82 | KDM4E (0.66) | KDM4EALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL21964041 | 0.81 | KDM4E (0.49) | KDM4EALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL13980334 | 0.80 | ALDH1A1 (0.44) | KDM4EALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL21200613 | 0.79 | KDM4E (0.62) | KDM4EALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL22902580 | 0.78 | IKBKB (0.53) | KDM4EALDH1A1MAPTKMT2AHSD17B10 | |
| SCHEMBL28416761 | 0.77 | POLB (0.51) | KDM4EALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL4874531 | 0.75 | KDM4E (0.60) | KDM4EALDH1A1MAPTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528802-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| CN-115710281-A | Isoxazolo [5,4-b ] pyridine FLT 3inhibitor and preparation method and application thereof | 南京中医药大学 | 2023-02-24 | — | — | CN | disclosed |
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220274982-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-01 | — | — | US | disclosed |
| EP-4005638-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021020363-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2021-02-04 | — | — | WO | disclosed |
| EP-3743063-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | Nurix Therapeutics, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| US-10266542-B2 | EZH2 inhibitors | Mirati Therapeutics, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| EP-2841435-B1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-7405225-B2 | Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1664025-B1 | PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| US-20050288285-A1 | Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | US | disclosed |
| US-6974870-B2 | Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | BOEHRINGER INGELHEIM PHAMACEUTICALS, INC. (US) | 2005-12-13 | — | — | US | disclosed |
| US-6964956-B2 | Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-11-15 | — | — | US | disclosed |
| EP-1513516-A1 | SUBSTITUTED 3-AMINO-THIENO(2,3-b) PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS ANDPROCESSES FOR PREPARING AND THEIR USES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2004111052-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE (MDR) | XENOVA LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
| US-20040180922-A1 | Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-09-16 | — | — | US | disclosed |
| US-20040053957-A1 | Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-03-18 | — | — | US | disclosed |
| WO-2003103661-A1 | SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053957-A1 | Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | NFKBIA, IKBKB, CHUK | KDM4E 1110/4885ALDH1A1 2562/4885MAPT 3942/4885 |
| US-20050288285-A1 | Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | NFKBIA, CHUK, IKBKB | KDM4E 831/4885ALDH1A1 2206/4885MAPT 3638/4885 |
| US-10266542-B2 | EZH2 inhibitors | EZH2, BMI1, EED | KDM4E 27/4885ALDH1A1 1969/4885MAPT 3203/4885 |
| US-20040180922-A1 | Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | NFKBIA, IKBKB, CHUK | KDM4E 1110/4885ALDH1A1 2562/4885MAPT 3942/4885 |
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | KDM4E 751/4885ALDH1A1 4576/4885MAPT 3167/4885 |
| US-12528802-B2 | Heterocyclic compound | GBA2, GBA1, GALC | KDM4E 2781/4885ALDH1A1 2563/4885MAPT 2291/4885 |
| US-20220274982-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | KDM4E 2610/4885ALDH1A1 1563/4885MAPT 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.